Physician profile
Azmathullah Khan
NPI 1073588943
$2,697.14
in general payments reported to CMS, 2019-2025
34 companies · $363 in 2025
The $363 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $293 · 2021: $201 · 2022: $323 · 2023: $495 · 2024: $729 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $425.27 | 2019-2023 | Enbrel, Tavneos |
| Ucb, INC. | $393.30 | 2019-2025 | Cimzia, Bimzelx, Briviact |
| Novartis Pharmaceuticals Corporation | $153.27 | 2020-2025 | |
| Glaxosmithkline, LLC. | $151.34 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $142.67 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Pfizer INC. | $110.29 | 2021 | |
| Cranial Technologies, INC | $102.92 | 2022-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $94.69 | 2021-2025 | Wainua |
| Organon LLC | $93.08 | 2023-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $84.00 | 2019-2024 | Strensiq |
| Emd Serono, INC. | $71.40 | 2020-2023 | Mavenclad |
| Genentech USA, INC. | $70.92 | 2019-2025 | Ocrevus Zunovo |
| Kiniksa Pharmaceuticals International, Plc | $69.17 | 2024 | Arcalyst |
| Biogen, INC. | $64.56 | 2022-2023 | Spinraza, Tysabri, Vumerity |
| Neurelis, INC. | $59.29 | 2023-2024 | Valtoco |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55.10 | 2024-2025 | |
| Sobi, INC | $54.82 | 2019-2024 | |
| Fresenius Kabi USA, LLC | $54.43 | 2025 | Tyenne |
| Neurocrine Biosciences, INC. | $50.53 | 2020 | |
| Harmony Biosciences LLC | $49.90 | 2023 | Wakix |
| Sanofi Pasteur INC. | $47.81 | 2021-2023 | |
| Fidia Pharma USA INC. | $46.63 | 2020-2024 | Hymovis |
| Actelion Pharmaceuticals US, INC. | $33.43 | 2023 | Opsumit |
| Rhythm Pharmaceuticals, INC. | $32.31 | 2023-2024 | Imcivree, Imcivree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.91 | 2024 | Spiriva Respimat |
| E.R. Squibb & Sons, L.L.C. | $24.70 | 2020-2021 | |
| Argenx US, INC. | $23.18 | 2022 | |
| Phadia US INC. | $19.76 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $19.05 | 2023 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $16.82 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $15.50 | 2020 | |
| Seqirus USA INC | $15.22 | 2022 | |
| Tris Pharma INC | $12.72 | 2019 | |
| Shire North American Group INC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azmathullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.